Table 1 Clinical characteristics of the subjects on the basis of blood pressure control in the total population

From: Increased arterial stiffness and cardiovascular risk prediction in controlled hypertensive patients with coronary artery disease: post hoc analysis of FMD-J (Flow-mediated Dilation Japan) Study A

 

All subjects

Blood pressure ≥130/80 mmHg

Blood pressure < 130/80 mmHg

 

Variables

(n = 447)

(n = 246)

(n = 201)

P value

Age, year

63.7 ± 8.7

63.3 ± 8.5

64.2 ± 9.0

0.28

Men, n (%)

387 (86.6)

213 (86.6)

174 (86.6)

0.99

Body mass index, kg/m2

24.9 ± 3.6

25.2 ± 3.7

24.5 ± 3.4

0.44

Systolic blood pressure, mmHg

129.7 ± 16.7

140.5 ± 13.5

116.4 ± 8.8

NA

Diastolic blood pressure, mmHg

75.1 ± 10.8

81.2 ± 9.3

67.7 ± 7.3

NA

Heart rate, bpm

66.6 ± 11.8

67.8 ± 12.2

65.1 ± 11.3

0.02

Total cholesterol, mmol/L

4.40 ± 0.81

4.41 ± 0.80

4.38 ± 0.83

0.77

Triglycerides, mmol/L

1.57 ± 1.07

1.52 ± 0.94

1.63 ± 1.21

0.29

HDL cholesterol, mmol/L

1.30 ± 0.33

1.32 ± 0.33

1.27 ± 0.34

0.12

LDL cholesterol, mmol/L

2.40 ± 0.71

2.42 ± 0.67

2.39 ± 0.76

0.69

Glucose, mmol/L

6.60 ± 2.04

6.61 ± 1.82

6.59 ± 2.28

0.92

HbA1c, %

6.4 ± 0.9

6.5 ± 0.97

6.4 ± 0.90

0.21

Creatinine, μmol/L

75.6 ± 21.0

74.7 ± 19.6

76.7 ± 22.5

0.32

Smoker, n (%)

55 (12.7)

34 (14.4)

21 (10.7)

0.26

Complications, n (%)

 Dyslipidemia

425 (95.1)

234 (95.1)

191 (95.0)

0.96

 Diabetes mellitus

170 (38.0)

100 (40.7)

70 (34.8)

0.21

 Prior myocardial infarction

242 (54.1)

131 (53.3)

111 (55.2)

0.68

 Prior coronary intervention

389 (87.0)

209 (85.0)

180 (89.6)

0.15

Medication use, n (%)

 Antiplatelet drugs

438 (98.0)

243 (98.8)

195 (97.0)

0.19

 ARBs/ACEIs

338 (75.6)

188 (76.4)

150 (74.6)

0.66

 β-blockers

231 (51.7)

121 (49.2)

110 (54.7)

0.24

 Calcium channel blockers

220 (49.2)

142 (57.7)

78 (38.8)

<0.001

 Diuretics

54 (12.1)

26 (10.6)

28 (13.9)

0.28

 Antidiabetic drugs

135 (30.2)

78 (31.7)

57 (28.4)

0.44

 Statins

385 (86.1)

215 (87.4)

170 (84.6)

0.39

Left ventricular ejection fraction, %

60.6 ± 10.0

60.5 ± 9.3

60.7 ± 10.7

0.85

Vessel diseased, n (%)

  1

241 (53.9)

129 (52.4)

112 (55.7)

0.79

  2

134 (30.0)

76 (30.9)

58 (28.9)

 

  3

72 (16.1)

41 (16.7)

31 (15.4)

 

LMT disease, n (%)

8 (1.8)

3 (1.2)

5 (2.5)

0.31

LAD disease, n (%)

268 (60.0)

135 (54.9)

133 (66.2)

0.02

LCX disease, n (%)

119 (26.6)

70 (28.5)

49 (24.4)

0.33

RCA disease, n (%)

160 (35.8)

91 (37.9)

69 (34.3)

0.56

BNP, pg/mL

36.3 ± 62.3

37.8 ± 74.8

34.6 ± 42.8

0.59

baPWV, cm/s

1662 ± 300

1729 ± 303

1580 ± 275

<0.001

  1. All the results are presented as mean ± SD
  2. HDL high-density lipoprotein, LDL low-density lipoprotein, ARB angiotensin receptor blocker, ACEI angiotensin-converting enzyme inhibitor, LMT left main trunk, LAD left anterior descending coronary artery, LCX left circumflex coronary artery, RCA right coronary artery, BNP brain natriuretic peptide, baPWV brachial–ankle pulse wave velocity, NA not applicable
Back to article page